Correction to: Afatinib in advanced NSCLC: a profile of its use

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1179-1977

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Correction to: Afatinib in advanced NSCLC: a profile of its use ; volume:34 ; number:4 ; day:16 ; month:2 ; year:2018 ; pages:196 ; date:4.2018
Drugs & therapy perspectives ; 34, Heft 4 (16.2.2018), 196, 4.2018

Creator: Deeks, Emma D.

Contributor: Keating, Gillian M.
SpringerLink (Online service)

DOI: 10.1007/s40267-018-0490-6

URN: urn:nbn:de:1111-2018052022047

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 11:01 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Deeks, Emma D.
Keating, Gillian M.
SpringerLink (Online service)

Other Objects (12)

Afatinib in advanced NSCLC: a profile of its use

Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Afatinib (NSCLC mit Plattenepithelhistologie) : Nutzenbewertung gemäß § 35a SGB V

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study

Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use

Quantification of [18F]afatinib using PET/CT in NSCLC patients: a feasibility study

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib

Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib

Stimulation of Eryptosis by Afatinib

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib

Afatinib in advanced NSCLC: a profile of its use

Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Afatinib (NSCLC mit Plattenepithelhistologie) : Nutzenbewertung gemäß § 35a SGB V

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study

Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use

Quantification of [18F]afatinib using PET/CT in NSCLC patients: a feasibility study

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib

Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib

Stimulation of Eryptosis by Afatinib

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib

Afatinib in advanced NSCLC: a profile of its use

Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Afatinib (NSCLC mit Plattenepithelhistologie) : Nutzenbewertung gemäß § 35a SGB V

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study

Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use

Quantification of [18F]afatinib using PET/CT in NSCLC patients: a feasibility study

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib

Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib

Stimulation of Eryptosis by Afatinib

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Correction to: Afatinib in advanced NSCLC: a profile of its use

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Afatinib in advanced NSCLC: a profile of its use

Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Afatinib (NSCLC mit Plattenepithelhistologie) : Nutzenbewertung gemäß § 35a SGB V

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study

Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use

Quantification of [18F]afatinib using PET/CT in NSCLC patients: a feasibility study

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib

Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib

Stimulation of Eryptosis by Afatinib

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib

Afatinib in advanced NSCLC: a profile of its use

Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Afatinib (NSCLC mit Plattenepithelhistologie) : Nutzenbewertung gemäß § 35a SGB V

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study

Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use

Quantification of [18F]afatinib using PET/CT in NSCLC patients: a feasibility study

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib

Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib

Stimulation of Eryptosis by Afatinib

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib

Afatinib in advanced NSCLC: a profile of its use

Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Afatinib (NSCLC mit Plattenepithelhistologie) : Nutzenbewertung gemäß § 35a SGB V

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study

Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use

Quantification of [18F]afatinib using PET/CT in NSCLC patients: a feasibility study

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib

Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib

Stimulation of Eryptosis by Afatinib

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib

Related objects

Reset password